Biovac to manufacture Pfizer Covid-19 vaccine for Africa

Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s global Covid-19 vaccine supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing facilities. To facilitate Biovac’s involvement in the process, technical transfer, on-site development and equipment installation activities will begin immediately.
Pfizer and BioNTech expect that Biovac’s Cape Town facility will be incorporated into the vaccine supply chain by the end of 2021. Biovac will obtain drug substance from facilities in Europe, and manufacturing of finished doses will commence in 2022. At full operational capacity, the annual production will exceed 100-million finished doses. All doses will exclusively be distributed within the 55 member states that make up the African Union.
Related
Viatris fined in Morocco over merger notification, sources say 22 Nov 2024 African drug supply chain gets smarter with IBM-powered AI platform 14 Nov 2024 Leadership shakeup at Moderna ahead of major vaccine rollouts 8 Nov 2024 Legal and regulatory insights into South Africa’s growing medical cannabis market 2 Oct 2024 Ghanaian minister visits Biovac to explore vaccine capabilities 14 Aug 2024 Biovac, EuBiologics partner to boost Africa meningitis vaccine 21 Jun 2024